DOCSLIB.ORG

FY15 NEIDL Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FY15 NEIDL Annual Report Annual Report , 2015 Blank page September 1, 2015 Letter from the Director This is the first annual report since the NEIDL Institute officially became a University Center on October 01, 2014. With this transition, the NEIDL changed its reporting structure from the Dean of the School of Medicine to the Associate Provost and Vice President for Research of Boston University. This change is important for two reasons. First, the change in reporting recognizes the significance of the current and future investments made by the University into the NEIDL, and for the field of emerging infectious diseases, as a focal point of research for the University. Second, it underscores the importance of embracing the breadth of research within in the University into the NEIDL as we recruit faculty. The study of emerging infectious diseases is by its very nature interdisciplinary, and leveraging expertise via joint recruitments with departments across the university will ensure a robust and innovative research portfolio necessary for the future success of the Institute. This diversity of expertise will be an important differentiator for the NEIDL. Coincident with the change, I had the privilege of being appointed as Director of the NEIDL. I do not take this responsibility lightly. With it comes not only the responsibility for establishing the scientific vision for the foreseeable future, together with many stakeholders across Boston University, but to also continue fostering the culture of safety in all that we do. We also have the responsibility to the public to be completely transparent in what we do. Public trust is essential to the future success of the NEIDL. Emerging infectious diseases research requires rigorous biologic containment facilities and practices, each requiring high levels of attention to the safety of the staff and the public. We aspire to be innovative not only in science, but in safety and safe practices. The NEIDL will also serve as a training center for the next generation of scientists, and this requires that we pass on the safety first culture to them as well. During this first year, the NEIDL completed the permitting process for undertaking biosafety level 3 (BSL-3) research, obtaining all remaining permits from the Boston Public Health Commission as well as the Centers for Disease Control. These were major hurdles, requiring the outstanding teamwork of the NEIDL staff. The hard work of facilities staff, members of Environmental Health and Safety, Security, and Research Occupational Health all played critical roles in the permitting process. All BSL-3 work will now be undertaken in the NEIDL; other BSL-3 containment research facilities on the medical campus have been or will be decommissioned shortly. We are also working to secure permits for BSL-4, and we look forward to having completed all requirements for BSL-4 work soon, and to begin to undertake work safely in this remarkable facility. To ensure that everyone in the NEIDL is part of the culture of safety, we instituted a “Biosafety and Biosecurity Grand Rounds” during this year, which engages staff throughout the NEIDL in continuing discussions about safety and security. These serve to provide a forum for frank exchanges of information between the NEIDL’s staff, faculty, and trainees, and keep our emphasis on safe and secure practices at the forefront. NEIDL Annual Report FY15 - page 1 We are, of course, here to do cutting edge science. During this year, our scientists have continued to be recognized for the quality of their research, setting a high bar for those we will recruit. Their quality is reflected not only in their excellence in publications, but their success in competing for external funding to support their science. Some of these successes are highlighted in this report. Our faculty also recruited a strong cadre of graduate students and postdoctoral fellows to their laboratories, a key component in our mission to train the next generation of scientists. We have also developed educational programs for the local public schools (“Identifying Infectious Diseases, aka ID2) and participated with news programs to disseminate science to the public, including our participation with Al Jazeera America’s TechKnow program for a piece on emerging infectious diseases research (http://america.aljazeera.com/watch/shows/techknow/articles/2015/2/23/inside-a-biosafety-level- four-lab.html). In sum, as we turn our attention to recruiting new faculty and further building the NEIDL research portfolio, we have used this year to set the expectations for science, education, safety and community engagement and outreach. Ronald B. Corley, Ph.D. Professor of Microbiology Director, National Emerging Infectious Diseases Laboratories NEIDL Annual Report FY15 - page 2 Table of Contents Mission and Strategic Plan …………………………………………………………….………………………………… 4 Faculty and Staff………………………………………………………………….…………………………………………… 5 Scientific Leadership ……………………………………………….…………………………………………… 5 Investigators…………………………………………………………………………………………………………… 6 Scientific Staff…………………………………………………………………………………………………………. 7 Students………………………………………………………………………………………………………………… 8 Administration………………………………………………………………………………………………………… 9 Animal Core Operations………………………………………………………………………………………..… 9 Community Relations……………………………………………………………………….……………………… 9 Environmental Health & Safety……………………………………………………………………………… 9 Facilities Maintenance and Operations……………………………………………………….…………… 10 Public Safety………………………………………………………………………………………………………….… 10 Organizational Chart…………………………………………………………………………………..…………… 11 Research…………………………………………………………………………………………………………………….…… 12 Faculty Recognition…………………………………………………………………………………….…………… 20 Publications…………………………………………………………………………………………………..………… 21 FY15 Funded Research………………………………………………………………………..……………..…… 28 Seed Funding…………………………………………………………………………………………………………… 30 Education and Training……………………………………………………………………….……….……………………… 31 Infectious Diseases Seminars………………………………………………………………………………….. 31 Biosecurity & Biosafety Grand Rounds……………………………………………………………………. 32 Community Outreach………………………………………………………………………….……………………………… 33 Highlights ………………….………………………………………………………………………………..………… 33 NEIDL Scientists serving in West Africa………………………………………………………………….. 35 Events and Programs …………………………………………………………………………………………………….……. 38 NEIDL Annual Report FY15 - page 3 Mission Statement and Strategic Plan The Boston University National Emerging Infectious Diseases Laboratories (NEIDL) mission is: To generate and translate fundamental knowledge on high priority emerging infectious diseases for the benefit of the public health, locally, nationally and globally. Emerging infectious diseases are defined as those that have newly appeared and been recognized in the population, or have existed but are rapidly increasing in incidence or in geographic range. To meet our missions the NEIDL will: 1. Perform innovative basic, translational and clinical research on emerging infectious diseases, especially those identified as high priority category A, B, and C agents (http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx), in order to develop diagnostic tests, treatments and vaccines to promote the public's health. 2. Provide education and training in these areas of research, in order to develop the next generation of scientists in this field, and to support a national response in the event of a biodefense emergency. 3. To establish a research facility with the highest attention to community and laboratory safety and security. To successfully implement and achieve these goals, NEIDL has developed and is implementing a strategic plan to: 1. Partner with academic departments across the university to recruit a cadre of investigators, as well as to develop research staff with expertise in the scientific disciplines required to investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents. We encourage and support the development of national and international research collaborations in order to carry out our mission. 2. Develop physiologically relevant models for the comparative study of these pathogens, mimicking as closely as possible the human disease process. Not only does this require that we recruit faculty with expertise in animal modeling and veterinarian pathology, but also develop the needed services to support these investigations. 3. As rapidly as possible move promising basic research to translational, preclinical and clinical research in animals and humans in partnership with appropriate collaborators. 4. Create and establish the methodologies needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents. 5. Train scientists and related support personnel in the requirements to perform maximum containment research in a safe and secure environment. 6. Maintain the flexibility needed to support a national response in the event of a biodefense emergency. 7. Ensure a "safety first" environment for the conduct of all activities in the NEIDL. NEIDL Annual Report FY15 - page 4 Faculty and Staff Scientific Leadership Ronald B. Corley, PhD Professor and Chair, Department of Microbiology Director, NEIDL Director, Immunology Core Dr. Corley’s Research interests: Innate and adaptive immunity Innate-adaptive interface Jerrold J. Ellner, MD Professor, Department of Medicine Section Chief, Infectious Diseases Associate Director, NEIDL Dr. Ellner’s research interests: TB and HIV interactions TB diagnostics Gerald T. Keusch, MD
Load more

Recommended publications
  • Protein–Protein Interactions, Dynamics Simulations and Free Energy Calculations
    molecules Article Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, Mpro and PLpro of SARS-CoV-2: Protein–Protein Interactions, Dynamics Simulations and Free Energy Calculations Devashan Naidoo 1,* , Pallab Kar 2, Ayan Roy 3,*, Taurai Mutanda 1 , Joseph Bwapwa 1, Arnab Sen 2 and Akash Anandraj 1 1 Centre for Algal Biotechnology, Mangosuthu University of Technology, P.O. Box 12363, Durban 4026, South Africa; [email protected] (T.M.); [email protected] (J.B.); [email protected] (A.A.) 2 Bioinformatics Facility, Department of Botany, University of North Bengal, Siliguri 734013, India; [email protected] (P.K.); [email protected] (A.S.) 3 Department of Biotechnology, Lovely Professional University, Phagwara 144411, India * Correspondence: [email protected] (D.N.); [email protected] (A.R.) Abstract: The emergence of COVID-19 continues to pose severe threats to global public health. The pandemic has infected over 171 million people and claimed more than 3.5 million lives to date. Citation: Naidoo, D.; Kar, P.; Roy, A.; We investigated the binding potential of antiviral cyanobacterial proteins including cyanovirin-N, Mutanda, T.; Bwapwa, J.; Sen, A.; scytovirin and phycocyanin with fundamental proteins involved in attachment and replication of Anandraj, A. Structural Insight into SARS-CoV-2. Cyanovirin-N displayed the highest binding energy scores (−16.8 ± 0.02 kcal/mol, the Binding of Cyanovirin-N with the −12.3 ± 0.03 kcal/mol and −13.4 ± 0.02 kcal/mol, respectively) with the spike protein, the main Spike Glycoprotein, Mpro and PLpro of protease (Mpro) and the papainlike protease (PLpro) of SARS-CoV-2.
    [Show full text]
  • Antiviral Cyanometabolites—A Review
    biomolecules Review Antiviral Cyanometabolites—A Review Hanna Mazur-Marzec 1,*, Marta Cegłowska 2 , Robert Konkel 1 and Krzysztof Pyr´c 3 1 Division of Marine Biotechnology, University of Gda´nsk,Marszałka J. Piłsudskiego 46, PL-81-378 Gdynia, Poland; [email protected] 2 Institute of Oceanology, Polish Academy of Science, Powsta´nców Warszawy 55, PL-81-712 Sopot, Poland; [email protected] 3 Virogenetics Laboratory of Virology, Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7A, PL-30-387 Krakow, Poland; [email protected] * Correspondence: [email protected] Abstract: Global processes, such as climate change, frequent and distant travelling and population growth, increase the risk of viral infection spread. Unfortunately, the number of effective and accessible medicines for the prevention and treatment of these infections is limited. Therefore, in recent years, efforts have been intensified to develop new antiviral medicines or vaccines. In this review article, the structure and activity of the most promising antiviral cyanobacterial products are presented. The antiviral cyanometabolites are mainly active against the human immunodeficiency virus (HIV) and other enveloped viruses such as herpes simplex virus (HSV), Ebola or the influenza viruses. The majority of the metabolites are classified as lectins, monomeric or dimeric proteins with unique amino acid sequences. They all show activity at the nanomolar range but differ in carbohydrate specificity and recognize a different epitope on high mannose oligosaccharides. The cyanobacterial lectins include cyanovirin-N (CV-N), scytovirin (SVN), microvirin (MVN), Microcystis viridis lectin (MVL), and Oscillatoria agardhii agglutinin (OAA). Cyanobacterial polysaccharides, peptides, and other metabolites also have potential to be used as antiviral drugs.
    [Show full text]
  • DEVELOPMENT and EVALUATION of HIV Gp120 RESPONSIVE MICROBICIDE
    DEVELOPMENT AND EVALUATION OF HIV gp120 RESPONSIVE MICROBICIDE FORMULATION FOR THE PREVENTION OF HIV SEXUAL TRANSMISSION A DISSERTATION IN Pharmaceutical Sciences and Chemistry Presented to the Faculty of the University Of Missouri-Kansas City in partial fulfillment of The requirements for the degree of DOCTOR OF PHILOSOPHY By Fohona S. Coulibaly B.S Chemical Engineering, INP-HB, Yamoussoukro, Ivory Coast, 2011 Kansas City, Missouri 2018 © 2018 FOHONA S. COULIBALY ALL RIGHTS RESERVED DEVELOPMENT AND EVALUATION OF HIV gp120 RESPONSIVE MICROBICIDE FORMULATION FOR THE PREVENTION OF HIV SEXUAL TRANSMISSION Fohona S. Coulibaly, Candidate for the Doctor of Philosophy Degree University of Missouri-Kansas City, 2018 ABSTRACT Sexual transmission of HIV remains the primary route (75 to 85%) of HIV infection among all new infection cases. Furthermore, women represent the most vulnerable population and are more susceptible to HIV infections than their male counterpart. Thus, there is an urgent need to develop topical (vaginal/rectal) microbicide formulations capable of preventing HIV sexual transmission. The objective of this dissertation is to develop a mannose specific, lectin-based topical microbicide formulation capable of targeting HIV gp120 for the prevention of HIV sexual transmission. In Chapters 1 and 2, the general hypothesis, aims and scope of this work are introduced. Chapter 3 covers the literature review of anti-HIV lectins and current delivery approaches. In Chapter 4, the binding interactions between the mannose specific lectin Concanavalin A (ConA) and glycogen from Oster, as well as mannan from Saccharomyces cerevisiae, were studied using a quartz crystal microbalance (QCM). The equilibrium dissociation constant describing the interaction between Con A and glycogen (KD = 0.25 μM) was 12 fold lower than the equilibrium dissociation constant describing the binding between Con A and mannan (KD = iii 2.89 μM).
    [Show full text]
  • Novel Antiretroviral Structures from Marine Organisms
    molecules Review Novel Antiretroviral Structures from Marine Organisms Karlo Wittine , Lara Safti´c,Željka Peršuri´c and Sandra Kraljevi´cPaveli´c* University of Rijeka, Department of Biotechnology, Centre for high-throughput technologies, Radmile Matejˇci´c2, 51000 Rijeka, Croatia * Correspondence: [email protected]; Tel.: +385-51-584-550 Academic Editor: Kyoko Nakagawa-Goto Received: 2 September 2019; Accepted: 19 September 2019; Published: 26 September 2019 Abstract: In spite of significant advancements and success in antiretroviral therapies directed against HIV infection, there is no cure for HIV, which scan persist in a human body in its latent form and become reactivated under favorable conditions. Therefore, novel antiretroviral drugs with different modes of actions are still a major focus for researchers. In particular, novel lead structures are being sought from natural sources. So far, a number of compounds from marine organisms have been identified as promising therapeutics for HIV infection. Therefore, in this paper, we provide an overview of marine natural products that were first identified in the period between 2013 and 2018 that could be potentially used, or further optimized, as novel antiretroviral agents. This pipeline includes the systematization of antiretroviral activities for several categories of marine structures including chitosan and its derivatives, sulfated polysaccharides, lectins, bromotyrosine derivatives, peptides, alkaloids, diterpenes, phlorotannins, and xanthones as well as adjuvants to the HAART therapy such as fish oil. We critically discuss the structures and activities of the most promising new marine anti-HIV compounds. Keywords: antiretroviral agents; anti-HIV; marine metabolites; natural products; drug development 1. Introduction Human immunodeficiency virus (HIV) infections pose a global challenge given that in 2017, according to the World Health Organization data, 36.9 million people were living with HIV and additional 1.8 million people were becoming newly infected globally (Table1) .
    [Show full text]
  • Algae-Derived Bioactive Molecules for the Potential Treatment of SARS-Cov-2
    molecules Review Algae-Derived Bioactive Molecules for the Potential Treatment of SARS-CoV-2 Md. Asraful Alam 1 , Roberto Parra-Saldivar 2 , Muhammad Bilal 3 , Chowdhury Alfi Afroze 4, Md. Nasir Ahmed 5 , Hafiz M.N. Iqbal 2,* and Jingliang Xu 1,* 1 School of Chemical Engineering, Zhengzhou University, Zhengzhou 450001, China; [email protected] 2 Tecnologico de Monterrey, School of Engineering and Sciences, Monterrey 64849, Mexico; [email protected] 3 School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China; [email protected] 4 Department of Biotechnology & Genetic Engineering, University of Development Alternative, Dhaka 1209, Bangladesh; chowdhuryalfi[email protected] 5 Biotechnology & Natural Medicine Division, TechB Nutrigenomics, Dhaka 1209, Bangladesh; [email protected] * Correspondence: hafi[email protected] (H.M.N.I.); [email protected] (J.X.) Abstract: The recently emerged COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has adversely affected the whole world. As a significant public health threat, it has spread worldwide. Scientists and global health experts are collaborating to find and execute speedy diagnostics, robust and highly effective vaccines, and therapeutic techniques to Citation: Alam, M..A.; tackle COVID-19. The ocean is an immense source of biologically active molecules and/or com- Parra-Saldivar, R.; Bilal, M.; Afroze, pounds with antiviral-associated biopharmaceutical and immunostimulatory attributes. Some spe- C.A.; Ahmed, M..N.; Iqbal, H.M.N.; cific algae-derived molecules can be used to produce antibodies and vaccines to treat the COVID-19 Xu, J. Algae-Derived Bioactive disease.
    [Show full text]
  • 13.02.2020 Reference Type: Journal Article Record Number
    ► Day 14 – 13.02.2020 Reference Type: Journal Article Record Number: 689 Author: Ahmad, Tauseef, Khan, Muhammad, Khan, Fazal Mehmood and Hui, Jin Year: 2020 Title: Are we ready for the new fatal Coronavirus: scenario of Pakistan? Journal: Human Vaccines & Immunotherapeutics Pages: 1-3 Short Title: Are we ready for the new fatal Coronavirus: scenario of Pakistan? ISSN: 2164-5515 DOI: https://doi.org/10.1080/21645515.2020.1724000 Abstract: Scenario of Pakistan Pakistan, is the most affected countries, has experienced many diseases outbreaks and other disasters. Geographically and politically China and Pakistan are closely connected as shown in Figure 3. A large number of Chinese people are working in Pakistan on different developmental projects (China Pakistan Economic Corridor, Dams, Gawdar Port), and on the other hand many Pakistanis are residing in China carrying out their studies, business and jobs. The outbreak of coronavirus has appeared during the peak travel time when the Chinese from Pakistan and around the world are traveling to China, while the Pakistani community, especially students, are traveling back to Pakistan due to winter break. One of such case has been reported on 24 January 2020 after a person traveled from China to Pakistan on 21 January 2020 via Dubai and was diagnosed for 2019-nCoV on 24 January.3 However, the case was not notified officially by the government of Pakistan. In the depicted situation, the future is very alarming. After the ending of Chinese New Year celebrations, the Chinese will travel back to their jobs abroad, which may result in an outbreak of the fatal virus infection in Pakistan and other countries.
    [Show full text]
  • Strengthening Health Systems While Responding to a Health Crisis
    Strengthening Health Systems While Responding to a Health Crisis: Lessons Learned by a Nongovernmental Organization During the Ebola Virus Disease Epidemic in Sierra Leone The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Cancedda, C., S. M. Davis, K. L. Dierberg, J. Lascher, J. D. Kelly, M. B. Barrie, A. P. Koroma, et al. 2016. “Strengthening Health Systems While Responding to a Health Crisis: Lessons Learned by a Nongovernmental Organization During the Ebola Virus Disease Epidemic in Sierra Leone.” The Journal of Infectious Diseases 214 (Suppl 3): S153-S163. doi:10.1093/infdis/jiw345. http:// dx.doi.org/10.1093/infdis/jiw345. Published Version doi:10.1093/infdis/jiw345 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:29408366 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA The Journal of Infectious Diseases SUPPLEMENT ARTICLE Strengthening Health Systems While Responding to a Health Crisis: Lessons Learned by a Nongovernmental Organization During the Ebola Virus Disease Epidemic in Sierra Leone Corrado Cancedda,1,2,4 Sheila M. Davis,1 Kerry L. Dierberg,1,2 Jonathan Lascher,1 J. Daniel Kelly,2,7,10 Mohammed Bailor Barrie,1,4,10 Alimamy Philip Koroma,13 Peter George,15 Adikali Alpha Kamara,14 Ronald Marsh,11 Manso S. Sumbuya,12 Cameron T. Nutt,1,4 Kirstin W.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,193,157 B2 Balzarini Et Al
    US0081931.57B2 (12) United States Patent (10) Patent No.: US 8,193,157 B2 Balzarini et al. (45) Date of Patent: Jun. 5, 2012 (54) ANTIVIRAL THERAPIES WO WO 97.33622 9, 1997 WO WOO3,0571.76 T 2003 (75) Inventors: Jan Balzarini, Heverlee (BE); Monika WO WOO3,061579 T 2003 Mazik, Braunschweig (DE) WO WO 2005/0244 16 * 3/2005 OTHER PUBLICATIONS (73) Assignees: K.U.Leuven Research & Development, Leuven (BE); Technische Universität Goff, PubMed Abstract (JGene Med3(6):517-28), Nov.-Dec. 2001.* Carolo Wilhelmina Zu Braunschweig, Bosseray et al., PubMed Abstract (Pathol Biol (Paris) 50(8):483-92), Braunschweig (DE) Oct. 2002. Razonable et al., PubMed Abstract (Herpes 10(3):60-5), Dec. 2003.* (*) Notice: Subject to any disclaimer, the term of this Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medi cine, 20th Edition, vol. 2, pp. 1739-1747, 1996.* patent is extended or adjusted under 35 Mizuochi et al., “HIV Infection and Oligosaccharides: A Novel U.S.C. 154(b) by 924 days. Approach to Preventing HIV Infection and the Onset of AIDS.” The Journal of Infection and Chemotherapy, vol. 5, No. 4, pp. 190-195, (21) Appl. No.: 12/067,681 1999. Mizutani et al., “Molecular Recognition of Carbohydrates by Zinc (22) PCT Filed: Sep. 21, 2006 Porphyrins: Lewis Acid Lewis Base Combinations as a Dominant Factor for Their Selectivity.” Journal of the American Chemical (86). PCT No.: PCT/BE2OO6/OOO104 Society, vol. 119, No. 38, pp. 8991-9001, 1997. S371 (c)(1), International Search Report and Written Opinion (PCT/BE2006/ (2), (4) Date: Mar.
    [Show full text]
  • An Update of the Recombinant Protein Expression Systems of Cyanovirin-N
    Lotfi H., et al., BioImpacts, 2018, 8(2), 139-151 doi: 10.15171/bi.2018.16 TUOMS Publishing BioImpacts http://bi.tbzmed.ac.ir/ Group Publish Free ccess An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development Hajie Lotfi1,2, Roghayeh Sheervalilou3, Nosratollah Zarghami1,2* 1 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 2 Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran 3 Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran Article Info Abstract Introduction: Human immunodeficiency virus (HIV) is a debilitating challenge and concern worldwide. Accessibility to highly active antiretroviral drugs is little or none for developing countries. Production of cost-effective microbicides to prevent the infection with HIV is a requirement. Cyanovirin-N (CVN) is known as a promising cyanobacterial lectin, capable Article Type: of inhibiting the HIV cell entry in a highly specific Review manner. Methods: This review article presents an overview Article History: of attempts conducted on different expression systems for the recombinant production of CVN. Received: 10 Aug 2017 We have also assessed the potential of the final recombinant product, as an effective anti-HIV Revised: 5 Nov. 2017 microbicide, comparing prokaryotic and eukaryotic expression systems. Accepted: 7 Nov. 2017 Results: Artificial production of CVN is a challenging task because the desirable anti-HIV ePublished: 16 Nov. 2017 activity (CVN-gp120 interaction) depends on the correct formation of disulfide bonds during Keywords: recombinant production. Thus, inexpensive and functional production of rCVN requires an Anti-HIV protein effective expression system which must be found among the bacteria, yeast, and transgenic plants, Bacteria for the subsequent satisfying medical application.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, MERCED Purification and Study Of
    UNIVERSITY OF CALIFORNIA, MERCED Purification and Study of CC Chemokine-Based Strategies to Combat Chronic Inflammation and HIV A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Quantitative and Systems Biology by Anna Faith Nguyen, B.S., University of California, Davis Committee in charge: Professor Michael Cleary, Chair of Advisory Committee Professor Andy LiWang Professor Patricia J. LiWang, Supervisor Professor Maria Zoghbi 2017 Copyright Anna Faith Nguyen, 2017 All Rights Reserved The dissertation of Anna Faith Nguyen, titled, “Purification and Study of CC Chemokine- Based Strategies to Combat Chronic Inflammation and HIV”, is approved, and is acceptable ion quality and form for publication on microfilm and electronically: _________________________________ Date _______________ Professor Andy LiWang _________________________________ Date _______________ Professor Maria Zoghbi Supervisor _________________________________ Date _______________ Professor Patricia J. LiWang Chair _________________________________ Date _______________ Professor Michael Cleary University of California, Merced 2017 iii To my friends, family, and especially husband. I love you all so much; thank you for your endless support and patience. And Marko, thank you for not popping out too soon. iv Table of Contents I. List of Figures………...…………………………………………………………….…vii II. List of Tables…………………………………………………………………………..x III. List of Abbreviations……………………………………………………..………….xi IV. Acknowledgements...………………………………..…………………………….xiii V. Vita for Anna Faith Nguyen………………………………………………...….......xiv VI. Abstract……………………………………………………………………..………,xv Chapter 1. Introduction…………………………………………………………………….….1 1.1 Introduction to CC Chemokines……………………………………………….….1 1.2 The Role of CC Chemokines in Chronic Inflammation……………………….7 1.3 The Role of CC Chemokines in HIV Infection…………………………….…….10 1.3.2 HIV Entry into Human Cells……………………………………….……10 1.3.2 HIV Latency in Human Cells…………………………………………...14 Chapter 2.
    [Show full text]
  • Strengthening Health Systems While Responding to a Health Crisis
    The Journal of Infectious Diseases SUPPLEMENT ARTICLE Strengthening Health Systems While Responding to a Health Crisis: Lessons Learned by a Nongovernmental Organization During the Ebola Virus Disease Epidemic in Sierra Leone Corrado Cancedda,1,2,4 Sheila M. Davis,1 Kerry L. Dierberg,1,2 Jonathan Lascher,1 J. Daniel Kelly,2,7,10 Mohammed Bailor Barrie,1,4,10 Alimamy Philip Koroma,13 Peter George,15 Adikali Alpha Kamara,14 Ronald Marsh,11 Manso S. Sumbuya,12 Cameron T. Nutt,1,4 Kirstin W. Scott,4 Edgar Thomas,1 Katherine Bollbach,1 Andrew Sesay,1,10 Ahmidu Barrie,1,10 Elizabeth Barrera,1 Kathryn Barron,1 John Welch,1,5 Nahid Bhadelia,1,6 Raphael G. Frankfurter,1,10 Ophelia M. Dahl,1 Sarthak Das,1 Rebecca E. Rollins,1 Bryan Eustis,1 Amanda Schwartz,1 Piero Pertile,1 Ilias Pavlopoulos,1 Allan Mayfield,1 Regan H. Marsh,1,3,4 Yusupha Dibba,1,10 Danielle Kloepper,1 Andrew Hall,1 Karin Huster,1,16 Michael Grady,1 Kimberly Spray,1 David A. Walton,1,2 Fodei Daboh,1,10 Cora Nally,1 Sahr James,1,10 Gabriel S. Warren,1 Joyce Chang,1 Michael Drasher,1 Gina Lamin,1,10 Sherry Bangura,1,10 Ann C. Miller,4 Annie P. Michaelis,1 Ryan McBain,1 M. Jana Broadhurst,1 Megan Murray,1,2,4 Eugene T. Richardson,1,2,8,9 Ted Philip,1 Gary L. Gottlieb,1 Joia S. Mukherjee,1,2,4 and Paul E. Farmer1,2,4 1Partners In Health, 2Division of Global Health Equity, and 3Department of Emergency Medicine, Brigham and Women’s Hospital, 4Department of Global Health and Social Medicine, Harvard Medical School, 5Department of Anesthesiology, Perioperative, and Pain Medicine, Boston
    [Show full text]
  • World View by Nahid Bhadelia Coronavirus: Hospitals Must Learn from Past Pandemics
    A personal take on science and society World view By Nahid Bhadelia Coronavirus: hospitals must learn from past pandemics Use methods honed in previous outbreaks to and separating them from others with similar symptoms. prepare for the next one, says Nahid Bhadelia. Countries with confirmed cases are sharing viral genetic What do sequences — which makes developing tests easier. Many hospitals in richer countries must decide whether he world that is grappling with 2019 novel you do patients should be cared for in specialized biocontain- coronavirus (2019-nCoV) is different from how when large ment units created for people with Ebola virus disease or it was during the SARS and H1N1 pandemics. numbers of in rooms assigned to those with other airborne diseases, The disease itself, and information and disin- such as tuberculosis and measles. But the demand for both formation, now travel faster than ever. people arrive could soon outstrip supply if the epidemic spreads, so hos- TI worked as a clinician in West Africa during the Ebola at facilities pitals could create a stepwise plan: one for dealing with a outbreak, and in New York City hospitals during the H1N1 with an handful of patients, and another for when large numbers of one. Now, I’m working in Boston, Massachusetts, to prepare sick patients cause a shortage of intensive-care beds. Hos- for potential cases of 2019-nCoV acute respiratory disease. unfamiliar pitals might need to work with nearby facilities to ensure And many of the challenges are the same as those faced in disease?” every person needing intensive care receives it.
    [Show full text]